Autologous platelet-rich fibrin (PRF) is a second-generation platelet concentrate derived from centrifuged blood1. PRF is a unique system that combines biocompatibility and biodegradability, and contains growth factors and peptides that promote tissue regeneration. Nowadays, this makes PRF the preferred choice for a variety of biomaterials. After centrifugation, PRF still combines not only the autologous growth factors found in the original blood, but also the cells involved in the wound healing process (see Fig.1.) 2,3. However, despite these positive properties, PRF does not have particularly pronounced antibacterial properties. As we know, the most common postoperative risk of minor surgeries is infection caused by membrane exposure and colonization of wound bacteria 4,5. Therefore, many studies combine PRF with drugs to reduce the risk of infections. Unfortunately, these studies show insufficient analysis and lack of data, such as, drug release time and amount. Only an understanding of the ability of these materials to be combined with other biomaterials and drugs will allow us to obtain new biomaterials with the necessary properties for use in many fields of medicine.